StockIQpro
NASDAQ:IRD

Opus Genetics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Opus Genetics, Inc.'s revenue grew 29.1% in fiscal 2025 to $14.2M while operating margin rose to −271.9%. The diluted share count rose 132.9%.Summary generated from Opus Genetics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$14.2M
Revenue growth+29.1%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−271.9%
Net margin−349.3%
ROICn/a
Return on equity−449.4%
Debt / equity0.07
Free cash flown/a
FCF marginn/a
Share count change+132.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue140191114
Operating income−2318−11−62−39
Net income−5718−10−58−50
Free cash flown/an/an/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations